Regression to the mean: implications for clinical trials of psychotropic agents in dementia.

Effective drug development depends on understanding and optimizing results from controlled clinical trials. A recent double-blind, randomized, controlled trial of the treatment of agitation in patients with Alzheimer's disease (AD) found no difference among the four arms of the study: haloperidol, trazodone, behavioral therapy, placebo. The current analysis was undertaken to further investigate the issues bearing on this outcome and to identify better means of detecting psychotropic effects in trials involving patients with AD. This was post hoc analysis of a clinical trial data set. Patients in the placebo group were divided into responders (25% reduction in symptoms), worseners (25% worsening in baseline agitation scores), and those without a change in symptoms. Analysis of the trial outcomes demonstrated that the reduction observed in the placebo group was of the same magnitude as predicted by regression to the mean. Patients exhibiting greater improvement had more severe baseline behavioral disturbances. The relatively modest severity of agitation and the low medication doses achieved in the study may have further contributed to the failure to distinguish among treatment groups. Research design adjustments such as collection of both screening and baseline measures to determine eligibility may limit the effects of regression to the mean on trial outcomes and reduce this challenge to clinical trials.

[1]  D. Jeste,et al.  Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group. , 1999, The Journal of clinical psychiatry.

[2]  H. Young,et al.  The screen for caregiver burden. , 1991, The Gerontologist.

[3]  S H Ferris,et al.  Assessing Patterns of Agitation in Alzheimer's Disease Patients with the Cohen‐Mansfield Agitation Inventory , 1997, Alzheimer disease and associated disorders.

[4]  P. Truax,et al.  Assessment of behavioral problems in dementia: the revised memory and behavior problems checklist. , 1992, Psychology and aging.

[5]  M F Weiner,et al.  The Behavior Rating Scale for Dementia of the Consortium to Establish a Registry for Alzheimer's Disease. The Behavioral Pathology Committee of the Consortium to Establish a Registry for Alzheimer's Disease. , 1995, The American journal of psychiatry.

[6]  B. Presnell,et al.  Density Estimation under Constraints , 1999 .

[7]  S H Ferris,et al.  A Multicenter Evaluation of New Treatment Efficacy Instruments for Alzheimer's Disease Clinical Trials: Overview and General Results , 1997, Alzheimer disease and associated disorders.

[8]  C J McDonald,et al.  How much of the placebo 'effect' is really statistical regression? , 1983, Statistics in medicine.

[9]  J. L. Mack,et al.  A Longitudinal Study of Behavioral Pathology Across Five Levels of Dementia Severity in Alzheimer's Disease: The CERAD Behavior Rating Scale for Dementia , 1997, Alzheimer disease and associated disorders.

[10]  A. Brett Treatment of Agitation in Alzheimer's Disease , 2000 .

[11]  J. Cohen-Mansfield,et al.  Agitated Behaviors in the Elderly: I. A Conceptual Review , 1986, Journal of the American Geriatrics Society.

[12]  H. Sackeim,et al.  A randomized, placebo-controlled dose-comparison trial of haloperidol for psychosis and disruptive behaviors in Alzheimer's disease. , 1998, The American journal of psychiatry.

[13]  Joseph P. Romano Bootstrap and randomization tests of some nonparametric hypotheses , 1989 .

[14]  D. Sultzer,et al.  A double-blind comparison of trazodone and haloperidol for treatment of agitation in patients with dementia. , 1997, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[15]  B. Lawlor,et al.  A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia , 1999, Neurology.

[16]  S. Folstein,et al.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.